Top Healthcare Stocks To Watch This Week

As medical experts and scientists discover diseases, healthcare companies are ready to meet these challenges by working hard to develop superior treatments and therapies with the patient’s best interests in mind.   Because of this, the healthcare sector manages to remain above the curve, which in turn leads to growth seen within the sector.

healthcarestocks.jpg

As the demand for innovative healthcare approaches rises, the opportunity for companies to invest and develop fresh technologies to does as well. With healthcare companies working to develop new methods to improve the quality of care, whether it be technology, devices or drugs, several healthcare stocks  are beginning to see higher activity in the markets.

Premier Health Group, Inc. (PHGRF) (PHGI) announced it is working with NexTech AR Solutions (NEXCF) to explore bringing augmented reality technology to its patient centric healthcare app to develop education tools for healthcare professionals and patients. Premier Health also recently announced the launch of a technology enabled mental health initiative to focus on providing app enabled mental health counselling for patients as well as growing its development team at Cloud Practice to support the build out of its patient centric platform and mobile app – a beta version of which will be available by end of Q2 will initially be extended to the 290 clinics in Premier Health’s ecosystem.

“At Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient centric telemedicine app,” said Dr. Essam Hamza, CEO. “AR has the potential to revolutionize both the access to data and the delivery of healthcare. The technology will help doctors and patients alike – doctors will have access to the latest and most relevant information about their patients while patients can use AR for self-education and improving the quality of treatment they receive.”

Premier Health’s other recent announcements include expansion plans to formally enter the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers to develop a partnership. The company is also in the process of closing on two operating pharmacies in Metro Vancouver and entered into a partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.

Axovant (AXGT) reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease. The cohort consisted of two patients with advanced Parkinson’s disease who received a one-time administration of the lowest dose of AXO-Lenti-PD and was generally well-tolerated, and no serious adverse events were reported.

“Our focus in this first cohort of the SUNRISE-PD study was on the safety and tolerability of AXO-Lenti-PD, as well as the evaluation of efficacy using well-validated, objective measures. These early data support the safety of the lowest dose of AXO-Lenti-PD, similar to what was observed with the earlier generation construct, ProSavin, and also suggest substantially greater biological activity than the highest dose of ProSavin previously tested,” said Dr. Gavin Corcoran, Executive VP of R&D. “These findings are highly encouraging, and we look forward to advancing to higher dose cohorts where we will explore the full clinical potential of AXO-Lenti-PD in patients with Parkinson’s disease.”

Axovant plans to proceed to the planned second dose cohort of AXO-Lenti-PD, with the first subject in this second cohort is expected to be dosed in the second quarter of 2019. Pavan Cheruvu, M.D., CEO, will be presenting at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019 at 12:00 PM (Eastern Time).

Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the first participant was enrolled in the RECOVERY study, a new Phase 3 study of Tonmya* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD).

“Tonix is committed to improving the lives of the millions who suffer from PTSD, especially military-related PTSD, and enrolling the first participant in the RECOVERY study is an important step towards achieving this goal,” said Seth Lederman, M.D., Tonix’s President and CEO. “We believe the innovative design features of the RECOVERY study, which are based on careful analyses of data from our prior PTSD trials, in addition to FDA feedback, may increase the probability of success of the RECOVERY study. We look forward to progressing enrollment and to anticipated topline results in the first half of next year.”

This news followed last week’s announced that the European Patent Office issued European Patent No. 3246031 to the company on February 27, 2019 is expected to provide market exclusivity until April 2029.The patent, “Method for Treating Neurodegenerative Dysfunction,” claims the use of TNX-601for treating neurocognitive dysfunction associated with corticosteroid treatment. Patents claiming the use of TNX-601, its structural analogs, and salts have previously been issued in the U.S., Canada and Europe.

biotechstocks.jpg


This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s